Evidence map›Paper›PMID 39792236›Full record

GuidelineInternational journal of hematology2025

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.

Yoshinobu Seki, Kohji Okamoto, Takayuki Ikezoe, Kazuma Yamakawa, Seiji Madoiwa, Toshimasa Uchiyama, Hidesaku Asakura, Shinya Yamada, Shin Koga, Hiroyasu Ishikura and 15 more

Abstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yoshinobu SekiDepartment of Hematology, Niigata University Medical and Dental Hospital/Niigata Cancer Center Hospital, Asahimachidori 1/Kawagishicho 2-15-3, Niigata, Niigata, 951-8510/951-8566, Japan. y-seki@med.niigata-u.ac.jp.ORCID http://orcid.org/0000-0001-6220-8657
Kohji OkamotoDepartment of Surgery, Kitakyushu City Yahata Hospital, Kitakyushu, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kazuma YamakawaDepartment of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Seiji MadoiwaDepartment of Clinical Laboratory Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Toshimasa UchiyamaDepartment of Laboratory Medicine, NHO Takasaki General Medical Center, Takasaki, Japan.
Hidesaku AsakuraDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Shinya YamadaDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Shin KogaDepartment of Internal Medicine, SBS Shizuoka Health Promotion Center, Shizuoka, Japan.
Hiroyasu IshikuraDepartment of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Takashi ItoDepartment of Hematology and Immunology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Toshiaki IbaDepartment of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mitsuhiro UchibaDepartment of Blood Transfusion and Cell Therapy, Kumamoto University Hospital, Kumamoto, Japan.
Kaoru KawasakiDepartment of Obstetrics and Gynecology, Faculty of Medicine, Kinki University, Higashiosaka, Japan.
Noriaki KawanoDepartment of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Satoshi GandoDepartment of Acute and Critical Care Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Shigeki KushimotoDivision of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yuichiro SakamotoDepartment of Emergency and Critical Care Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Toshihisa TamuraDepartment of Surgery 1, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kenji NishioDepartment of General Medicine, Uda City Hospital, Uda, Japan.
Mineji HayakawaDivision of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Takeshi MatsumotoDepartment of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu, Japan.
Toshihiko MayumiDepartment Intensive Care, Japan Community Healthcare Organization Chukyo Hospital, Nagoya, Japan.
Hideo WadaAssociated Department With Mie Graduate School of Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.
Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study discusses disseminated intravascular coagulation (DIC) associated with solid cancers and various vascular abnormalities, both of which generally exhibit chronic DIC patterns. Solid cancers are among the most significant underlying diseases that induce DIC. However, the severity, bleeding tendency, and progression of DIC vary considerably depending on the type and stage of the cancer, making generalization difficult. Moreover, during the process of creating these guidelines, it became apparent that despite solid cancers being a major underlying condition for DIC, there is a lack of high-quality research on DIC associated with solid cancers. Nevertheless, we developed recommendations for clinical questions (CQs) regarding the use of heparin and recombinant thrombomodulin. Additionally, statements concerning these five questions were provided. DIC associated with various vascular abnormalities, is characterized by hyperfibrinolytic activity and linked to underlying conditions such as aortic aneurysm, aortic dissection, vasculitis syndromes, and vascular malformations. These conditions must always be considered differential diagnoses when unexplained thrombocytopenia or bleeding tendencies are observed. Although no evidence was found to support the assignment of recommendation levels, three statements were made. However, traumatic vascular abnormalities have not been discussed in this context.

Indexed as

Disseminated Intravascular CoagulationNeoplasmsVascular DiseasesAnticoagulantsDisease ManagementHeparinHumansJapanThrombomodulinAnticoagulantsHeparinThrombomodulinDICHeparinRecombinant thrombomodulinSolid cancerVarious vascular abnormalities

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.